Skip to main content

Table 7 Clinical factors and genotypes influencing survival in multivariate analyses

From: Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker

 

TTP

OS

 

HR (95%CI)

p-value

HR (95%CI)

p-value

TS 6-bp deletion in 3'UTR

0.561 (0.331–0.950)

0.032

0.553 (0.285–1.072)

0.079

XPD-Arg156Arg

0.705 (0.407–1.220)

0.210

0.923 (0.456–1.867)

0.823

XPD-Asp312Asn

1.956 (0.902–4.240)

0.089

0.802 (0.281–2.286)

0.679

Performance (ECOG 0–1 vs. 2)

1.973 (1.034–3.762)

0.073

1.638 (0.816–3.288)

0.165